STOCKWATCH: Venture capital sees new signs of life as IPOs, M&A create value
This article was originally published in Scrip
Was it the usual year-end burst of investment activity or was the fourth quarter spike in US biotechnology venture capital investment spurred by 2013's vigorous market for initial public offerings and high-value mergers and acquisitions?
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.